Identification of a Human Homologue of the Schizosaccharomyces pombe rad17+ Checkpoint Gene*

Andrew E. ParkerDagger §, Inez Van de WeyerDagger , Marc C. LausDagger , Peter Verhasselt, and Walter H. M. L. LuytenDagger parallel

From the Dagger  Department of Experimental Molecular Biology and the  Department of Applied Molecular Biology, Janssen Research Foundation, Turnhoutseweg 30, B-2340 Beerse, Belgium

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In the fission yeast Schizosaccharomyces pombe the rad17+ gene is required for both the DNA damage-dependent and the DNA replication-dependent cell cycle checkpoints. We have identified a human cDNA homologue of the S. pombe rad17+ checkpoint gene, designated Hrad17. Hrad17 has 49% identity to the S. pombe rad17+ sequence at the DNA level and 49% identity and 72% similarity at the amino acid level. Northern blot analysis indicates elevated levels of expression in testis and in cancer cell lines. Chromosomal localization by fluorescence in situ hybridization indicates that Hrad17 is located on chromosome 4q13.3-21.2. This region is subject to loss of heterozygosity in several human cancers. To begin to understand the protein-protein interactions of the human checkpoint machinery, we have used the yeast two-hybrid system to examine potential interactions between Hrad1, Hrad9, and Hrad17. We demonstrate a physical interaction between Hrad17 and Hrad1 but no interaction with Hrad9.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cell cycle checkpoints are regulatory pathways ensuring that the events of the cell cycle are completed with high fidelity and in an orderly fashion (reviewed in Refs. 1-3). When cells are subjected to conditions that interfere with DNA replication or cause damage to DNA, a signal is sent to halt cell cycle progression, thus permitting cell cycle phase completion or DNA repair (1-3). The loss of checkpoint control in mammalian cells results in genomic instability, leading to the amplification, rearrangement, or loss of chromosomes, events associated with tumor progression (2, 4). In Schizosaccharomyces pombe the products of six genes: rad1+, rad3+, rad9+, rad17+, rad26+, and hus1+ have been identified as essential components of the checkpoint pathways (5). Several of the S. pombe checkpoint genes have structural homologues in the budding yeast, and further conservation across eukaryotes has recently been demonstrated with the cloning of two human homologues of S. pombe rad3+, ATM (ataxia telangiectasia mutated) (6) and ATR (ataxia telangiectasia and rad3+ related) (7, 8); a human homologue of S. pombe rad9+, Hrad9 (9); and a human homologue of S. pombe rad1+, Hrad1 (49).

Currently, little is known about the biochemistry of checkpoint control; however, the identification and characterization of human homologues of yeast checkpoint genes provides clear evidence that checkpoint pathways are conserved between mammals and yeast. The genetic data in yeast suggest that a complex of proteins mediates the monitoring of replication-specific structures and damaged DNA (10), and recent biochemical studies in yeast and humans suggest that the cell cycle arrest in response to DNA damage is brought about by the activation of a signal transduction pathway involving the protein kinases ATM/ATR and Hchk1 resulting in inhibitory phosphorylation of Cdc25 and subsequent stabilization of the inhibitory Tyr15 phosphorylation of Cdc2 (7, 11-13).

The S. pombe rad17 mutant is defective in both the DNA damage-dependent and the DNA replication-dependent checkpoints (14). The rad17+ gene has been cloned (15) and shows significant sequence similarity with Saccharomyces cerevisiae RAD24 and components of mammalian replication factor C, which are required to load the replicative DNA polymerases delta  and epsilon  onto primed DNA templates (16-19). Rad17 is not a functional homologue of a replication factor C subunit, although the sequence similarity may reflect some shared biological activity such as association with elements of the replication machinery or binding of specific DNA structures (15).

In this report we describe the cloning and characterization of a novel human cDNA, designated Hrad17, which is highly similar to the S. pombe rad17+ checkpoint gene. We also demonstrate that Hrad17 interacts with the recently identified Hrad1 but not Hrad9.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cloning and Sequencing of Human rad17-- A search for sequences similar to S. pombe rad17+ was carried out using the TBLASTN program (20) against the proprietary LifeSeq® data base (Incyte Pharmaceuticals Inc., Palo Alto, CA) as well as public domain data bases such as GenBankTM. Deduced amino acid sequences were aligned using the CLUSTALW program, and similarity was determined with a blosum62 amino acid substitution matrix. Clones with significant sequence similarity were ordered from Incyte or the Merck/Washington University EST1 collection, and the complete sequence of their inserts was determined. DNA sequencing was carried out on double-stranded plasmid DNA with dye-terminator chemistry as prescribed by the manufacturer (Perkin-Elmer/Applied Biosystems), and the products were resolved on an ABI PrismTM 377 Automated Sequencer. The complete DNA sequences of relevant inserts were aligned as described. The 5' end of the longest cDNA was extended by 5' RACE-PCR according to the manufacturer's instructions (CLONTECH). Two gene-specific primers were designed to the 5' end of the putative Hrad17 ORF: GSP1(5'-TTCTATGACTTGAGTTATTCACACC-3') and GSP2 (5'-GGCAGTAATAGTAGAGACGCCAC-3'). These were used in a nested PCR reaction with Marathon-Ready human placental cDNA (CLONTECH) as the template. The first PCR reaction made use of the GSP1 PCR primer for the 3' end, combined with the AP1 primer from CLONTECH that is complementary to an adaptor ligated to the 5' end of all Marathon-Ready cDNAs. The second PCR reaction started from 1-5 µl of the first and used the GSP2 in combination with a nested AP2 primer (CLONTECH). The reaction conditions for the first RACE-PCR were 30 cycles of 30 s at 95 °C, 30 s at 65 °C, and 1 min at 72 °C. The subsequent nested PCR consisted of two-step cycles, each containing a 30-s denaturation step at 95 °C and a combined annealing and elongation step for 2 min, which was carried out at 72 °C for the first five cycles, at 70 °C for the five subsequent cycles, and at 68 °C for the remaining 25 cycles. The reaction products were resolved by agarose gel electrophoresis, and specific reaction products were excised from the gel, purified using the QIAQuick gel extraction kit (Qiagen) and ligated into the pCR2.1-TOPO vector (Invitrogen). The insert sequence of eight independent clones was determined and compared with the putative Hrad17 partial cDNA sequence. The 5' RACE clones extended the partial Hrad17 sequence to a putative initiation codon as determined by alignment with the S. pombe rad17 sequence.

PCR primers were designed to amplify the complete Hrad17 ORF (OAP094, 5'-GCCGAATTCATGAATCAGGTAACAGACTGGGTT-3', and OP076, 5'-GGCGGATCCTCGAGTCTGTCCCATCACTCTCGTAGT-3') to enable subcloning into various expression vectors. The complete ORF was PCR-amplified from cDNA prepared from human SK-N-MC neuroblastoma cells using the following PCR reaction conditions: 30 cycles of 30 s at 95 °C, 30 s at 64 °C, and 2 min at 75 °C. The amplification products were directly cloned into the pCR2.1-TOPO vector (Invitrogen), and the DNA sequence from three independent clones of Hrad17 was determined.

Northern Analysis-- Two multiple tissue Northern blots (CLONTECH) and a cancer cell line Northern blot (CLONTECH) were hybridized with a DNA probe corresponding to the complete Hrad17 ORF labeled with [alpha -32P]dCTP by random hexamer priming using the Prime-a-Gene Kit (Promega). The blots were washed at high stringency (0.1 × SSC, 0.1% SDS, 50 °C, 2 × 20 min) and exposed to Kodak X-Omat autoradiography film with intensifying screens at -70° C. The blots were then rehybridized with a human beta -actin probe (CLONTECH) labeled with [alpha -32P]dCTP as described above. The films were scanned, and quantification of the bands was performed with the program Image Master 1D (Amersham Pharmacia Biotech).

S. pombe Culture and Plasmids-- S. pombe was cultured by standard techniques (21). The genotypes of the strains used are as follows: APY002, h+ leu1-32 ura4-D18 ade6-M216, and GBY192, h+ rad17::ura4+, leu1-32, ura4-D18, ade6-M216. The complete ORF coding for Hrad17 was cloned into the SmaI site of the S. pombe expression vector pREP3X (22) using standard techniques. Transformation of S. pombe was carried out by electroporation (23).

Fluorescence in Situ Hybridization (FISH) Studies-- The complete Hrad17 ORF was biotinylated with dATP using the Life Technologies, Inc. BioNick labeling kit (24). FISH mapping was carried out by SeeDNA Inc. (Toronto, Ontario, Canada) (25, 26) as described previously for Hrad1 (50).

Two-hybrid Analysis-- The MATCHMAKER Two-Hybrid System 2 (CLONTECH) was used to examine protein-protein interactions. The complete Hrad1A, Hrad1B, Hrad9, and Hrad17 ORFs were PCR-amplified and cloned into the pAS2-1 DNA-binding domain vector (CLONTECH) and the pACT2 activation domain vector (CLONTECH) using the following primers: Hrad1A for pAS2-1: OML004 (5'-GCCGAATTCATGCCCCTTCTGACCCAACAGA-3') and OML002 (5'-CTGCCTAGGTCAAGACTCAGATTCAGGAACTTC-3'); Hrad1A for pACT2: OML003 (5'-AAGGATCCGAATGCCCCTTCTGACCCAACAGA-3') and OML001 (5'-TAGCTCGAGTCAAGACTCAGATTCAGGAACTTC-3'); Hrad1B for pAS2-1: OAP101 (5'-GCCGAATTCATGTGTTACCAAGGT-3') and OML002; Hrad1B for pACT2: OAP102 (5'-GGGGATCCGAATGTGTTACCAAGGT-3') and OML001; Hrad9 for pAS2-1: OAP079 (5'-ACTCATATGAAGTGCCTGGTCACG-3') and OAP080 (5'-CTGCCTAGGTCAGCCTTCACCCTC-3'); Hrad17 for pAS2-1: OAP094 and OAP082 (5'-CTGCCTAGGCTATGTCCCATCACT-3'); and Hrad17 for pACT2: OAP095 (5'-GGGGATCCGAATGAATCAGGTAACAGACTGGGTT-3') and OAP088 (5'-GAGCTCGAGCCTATGTCCCATCACT-3'). The DNA sequences of all inserts were verified. The S. cerevisiae reporter strain was Y187 (Mat-alpha ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112 gal4Delta , met-, gal80Delta , URA3::GAL1UAS-GAL1TATA-lacZ). All plasmids were transformed individually and in all pair-wise combinations. Transformants were plated on synthetic defined medium lacking the appropriate amino acids (27). Colony lifting and detection of beta -galactosidase activity on filters and in liquid culture was carried out as prescribed by the manufacturer (CLONTECH).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Identification of a Human Homologue of S. pombe rad17+-- A human expressed sequence tag cDNA clone (number 515944) was identified in the proprietary LifeSeq® data base (Incyte Pharmaceuticals Inc., Palo Alto, CA) using the TBLASTN homology searching program (20) with the S. pombe rad17+ amino acid sequence as the query. This clone was purchased from Incyte Pharmaceuticals and DNA sequence analysis of the 1.9-kb insert revealed an incomplete ORF that was highly similar to the S. pombe Rad17 amino acid sequence. Further searches of the public data bases using the clone 515944-derived DNA sequence as the query sequence identified several expressed sequence tags with significant sequence similarity. One of these (accession number AA287094) extended the putative Hrad17 sequence in a 5' direction and maintained the similarity to S. pombe rad17. This sequence did not extend to the 5' end of the ORF, and comparison of the derived amino acid sequence with the S. pombe rad17+ sequence suggested that approximately 60 nucleotides were missing. To complete the putative Hrad17 ORF, a 5' RACE-PCR was carried out using a Marathon-Ready human placental cDNA library (CLONTECH) and two gene-specific primers. Approximately 350 nucleotides of novel 5' DNA sequence were obtained, including 57 nucleotides required to complete the Hrad17 ORF and 300 nucleotides of 5'-untranslated region. Termination codons were present in all three reading frames in the 80 nucleotides immediately 5' to the putative Hrad17 initiation codon, indicating that we had isolated the complete coding region (Fig. 1). The full-length Hrad17 ORF was then amplified from cDNA prepared from human SK-N-MC neuroblastoma cells, and the insert DNA sequence from three independent clones was determined. The complete coding region of Hrad17 is 2010 nucleotides in length and has 49% identity to the S. pombe rad17+ sequence at the DNA level and 49% identity and 72% similarity at the amino acid level (Fig. 2). The Hrad17 sequence has been deposited into GenBankTM under accession number AJ004977. Hrad17 also has significant sequence similarity to S. cerevisiae RAD24 (Fig. 2). The Hrad17 cDNA encodes a protein with a predicted molecular mass of approximately 71 kDa.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1.   The nucleotide sequence (GenBankTM accession code AJ004977) and predicted amino acid sequence of human Rad17. The consensus polyadenylation site is underlined; start and stop codons are in bold type.


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 2.   Amino acid sequence alignment between human Rad17, S. pombe Rad17, and S. cerevisiae RAD24 obtained with the CLUSTALW alignment program. Identical residues are highlighted in black and conserved residues are highlighted in gray. The putative nucleotide-binding domain is underlined.

Northern Blot Analysis for Hrad17-- The transcript profile of Hrad17 was examined by probing two multiple tissue Northern blots (CLONTECH) and a cancer cell line Northern blot (CLONTECH) with a probe corresponding to the complete Hrad17 ORF. A single transcript of approximately 3.0 kb was identified for Hrad17. The blots were also hybridized with a beta -actin probe to demonstrate equal loading of RNA across all lanes. The Hrad17 transcript was present in all tissues examined and was highly elevated in testis. Although the beta -actin signal is slightly elevated in the cancer cell lines when compared with the normal tissue blots, it is clear that the level of Hrad17 transcript is dramatically elevated in the cancer cell lines examined (Fig. 3). Because the Hrad17 sequence that we have identified is over 2800 bp long, it is likely to include most of the 5'- and 3'-untranslated region, considering that a typical mammalian poly(A) tail can be several hundred nucleotides long. The presence of an oligo(dT) stretch at the 3' end of the clone supports the conclusion that we have the full 3'-untranslated region.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 3.   Northern blot analysis of Hrad17. A, the multiple tissue and cancer cell line Northern blots (CLONTECH) were hybridized in parallel with a cDNA probe corresponding to the Hrad17 ORF. RNA size markers are indicated. The blots were then rehybridized with a human beta -actin cDNA probe (CLONTECH) to verify that comparable amounts of RNA are present across lanes and that the RNA samples show no sign of degradation. Exposure times were overnight for the Hrad17 probe and 30 min for the beta -actin probe. For either probe, all steps of the procedure (hybridization, washing, and exposure) were carried out in parallel for the three blots. B, quantitation (arbitrary units) using scanning densitometry of autoradiograph of blot shown in panel A.

Hrad17 Does Not Complement the S. pombe rad17 Checkpoint Phenotypes-- Complementation has often been used to demonstrate biological activity for mammalian homologues of yeast proteins (9, 28). We examined whether Hrad17 could complement the UV irradiation (DNA damage-dependent checkpoint) and hydroxyurea (DNA replication-dependent checkpoint) sensitivity phenotypes of an S. pombe rad17::ura4+ strain. Hrad17 was cloned into the S. pombe expression vector pREP3x (22) and transformed into wild type and rad17::ura4+ cells. Transformants were exposed to varying doses of UV or transiently exposed to 10 mM hydroxyurea as described previously (15). We observed no complementation of the UV or hydroxyurea sensitivity phenotypes (data not shown).

Hrad17 Is Located on Chromosome 4q13.3-21.2-- The chromosomal position of Hrad17 was determined to establish whether loss of heterozygosity associated with Hrad17 might be linked with any known disease. The 2.6-kb cDNA corresponding to expressed sequence tag clone number AA287094 was used as a probe for FISH mapping. Under the conditions used, the hybridization efficiency was approximately 71% for the probe (among 100 checked mitotic figures, 71 showed signals on one pair of chromosomes). No additional locus was picked up by FISH detection under the conditions used. The 4',6-diamidino-2-phenylindole (DAPI) banding pattern was used to establish that Hrad17 localizes to the long arm of chromosome 4 (25). The detailed position was further determined based upon the analysis of 10 photographs leading to the conclusion that Hrad17 is located on human chromosome 4q13.3-q21.2 (Fig. 4). Loss of heterozygosity of this region of chromosome 4 has been linked to a variety of human neoplasias including breast cancer, hepatocellular carcinoma, and small cell lung cancer (29-34).


View larger version (128K):
[in this window]
[in a new window]
 
Fig. 4.   Chromosomal localization of the Hrad17 gene determined by FISH analysis. A, photograph of metaphase chromosome spread labeled with fluorescent Hrad17 cDNA probe. B, photograph of the same mitotic figure stained with DAPI to identify chromosomes and reveal chromosome band patterns. Comparison with panel A shows the FISH signal is located on chromosome 4. C, idiogram of chromosome 4. The signal was further localized to 4q13.3-21.2 by determination of the distribution of signals from 10 independent photographs.

Hrad17 Interacts with Hrad1-- The yeast two-hybrid system has been used extensively to examine protein-protein interactions (35-37). We cloned Hrad17, Hrad9, and two forms of Hrad1 generated by alternative splicing (49), into the yeast two-hybrid expression vectors pAS2-1 and pACT (CLONTECH) and then transformed them individually or as pair-wise combinations into S. cerevisiae strain Y187 (CLONTECH). Transformants were assayed for beta -galactosidase activity either on filter lifts or using O-nitrophenyl beta -D-galactopyranoside as substrate as described by the manufacturer (CLONTECH). The beta -galactosidase activity was high in cells transformed with Hrad17 combined with either form of Hrad1, indicating a positive interaction (Fig. 5). In addition, Hrad17 was able to interact with itself to a lesser extent. Hrad9 did not show any interaction with itself nor with Hrad1 or Hrad17 (Fig. 5). The interaction between Hrad17 and Hrad1 was only observed when Hrad1 was fused with the GAL4 activation domain. We interpret this to mean that the 163-amino acid GAL4 DNA-binding domain fused to the N terminus of Hrad1 was hindering the interaction with Hrad17.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Hrad17 interacts with Hrad1. S. cerevisiae Y187 cells were transformed with the indicated full-length cDNAs coding for Hrad1A, Hrad1B, Hrad9, and Hrad17 or pair-wise combinations thereof. Two separate colonies for each transformation were assayed for beta -galactosidase activity using the liquid O-nitrophenyl beta -D-galactopyranoside assay as described. The results shown are from duplicate samples of two separate experiments (n = 4; mean ± S.D.), normalized to the control sample transformed with plasmids pVA3-1 and pTD1, which encode fusion proteins of the DNA-binding domain and activator domain, respectively, that provide a positive control for interacting proteins (murine p53 and SV40 large T antigen).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We have identified a human cDNA encoding a protein that shares significant sequence similarity with the S. pombe Rad17 protein and the S. cerevisiae RAD24 protein. Alignment of these sequences identifies several blocks of sequence similarity that are conserved between the human and yeast proteins and the human replication factor C subunits (15). One of these contains the consensus sequence for a nucleotide-binding domain. This domain is required for Rad17 function in S. pombe (15). The other regions of sequence similarity are not reminiscent of any defined functional domain but may reflect shared biological activity such as association with elements of the replication machinery or binding of specific DNA structures (15).

The Hrad17 transcript is present in all tissues that we examined and increased in all the cancer cell lines examined, suggesting either that transcription of Hrad17 is proliferation-dependent or that it is increased in response to the genomic instability of cancer cell lines. The level of Hrad17 transcript in testis is approximately 10-fold that seen in other tissues. Several yeast cell cycle checkpoint genes play important roles in meiosis (38), and recently ATM and ATR (the human homologue of S. pombe Rad3) were shown to be highly expressed in testis where they interact with meiotic chromosomes. This suggests a direct role for these proteins in recognizing and responding to DNA strand interruptions that occur during meiotic recombination (39). Hrad1 is also highly expressed in testis (49), suggesting that Hrad1 and Hrad17 may form part of a recognition complex in association with ATM or ATR.

Loss of checkpoint function has been shown to lead to genomic instability even in the absence of exogenous DNA damage (40). In man the p53 gene and the ATM gene are required for the G1-S phase checkpoint (41, 42). These genes also act as tumor suppressors (43-46), suggesting that it is likely that other checkpoint genes will act as tumor suppressors. We have shown that Hrad17 resides on chromosome 4 position q13.3-21.2. Loss of heterozygosity of this region of chromosome 4 has been linked to a variety of human neoplasias including breast cancer (29), hepatocellular carcinoma (30), and small cell lung cancer (13, 32). Consequently, Hrad17 should be considered as a candidate tumor suppressor gene on chromosome 4q. There is also evidence for the presence of an as yet unidentified gene on chromosome 4q that regulates DNA replication in response to DNA damage (33) and that is involved in the G1 arrest in cellular senescence (34). Hrad17 should also be considered as a potential candidate for these gene functions.

Demonstration of an interaction between Hrad17 and Hrad1 provides further evidence that we have identified the human homologue of S. pombe rad17. In fission yeast these two gene products act early in both the DNA damage-dependent and DNA replication-dependent checkpoint pathways, and mutants in either gene have similar phenotypes. In the budding yeast, RAD24 and RAD17 (the homologue of S. pombe rad1) are only required for the DNA damage-dependent checkpoint and have been shown to function in conjunction with MEC1 to activate DNA degradation (47), leading to the suggestion that there is a requirement to process single- or double-stranded breaks such that single-stranded DNA is exposed to activate the checkpoint (47, 48). Two forms of Hrad1 have been identified; Hrad1A which has an exonuclease activity and Hrad1B, an inactive N-terminal truncation of Hrad1A (49). We show in our two-hybrid assay that Hrad17 interacts with both forms of Hrad1. We also find that Hrad17 is able to interact with itself suggesting the presence of a multi-subunit complex consisting of Hrad1 and one or more Hrad17 molecules. We were unable to demonstrate the interaction between Hrad17 and Hrad1 when Hrad1 was expressed as a GAL4 DNA-binding domain fusion. Given the small size of Hrad1 we interpret these results to indicate that the fusion is inhibiting the interaction with Hrad17. In the absence of more sophisticated biochemical reagents such as antibodies to Hrad1 and Hrad17, we are unable to confirm the interaction between Hrad1 and Hrad17 by an independent method. Given the sequence similarity between Hrad17 and replication factor C, it is possible that Hrad17 is a DNA-binding protein or interacts with DNA replication proteins. Hrad17 might then act to bring other components of the checkpoint complex such as Hrad1 into close proximity with DNA. The interaction with Hrad1 would provide the exonuclease activity required for the degradation of DNA as proposed by Lydall and Weinert (47).

Hrad17 may also preferentially recognize damaged DNA; however, to assess any potential DNA binding activity we will need to purify Hrad17. Our attempts to express and purify Hrad17 overexpressed in Escherichia coli have been unsuccessful. We find that Hrad17 is extremely unstable when overexpressed, a situation that has also been observed for the S. pombe Rad17 protein.

In summary, these results describe a human homologue of S. pombe Rad17 that interacts with Hrad1 but not Hrad9. This provides further evidence of the conservation between yeast and mammals of checkpoint pathways at the molecular level. A detailed analysis of the interactions between Hrad17 and other checkpoint and DNA replication proteins and a biochemical analysis of the properties of Hrad17 are now required to fully establish the role that this protein plays in cell cycle checkpoint control.

    ACKNOWLEDGEMENTS

We thank Jörg Sprengel for bioinformatics assistance and Grant Brown for providing the S. pombe strains.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Cardiovascular Metabolism and Musculoskeletal Research Dept., Zeneca Pharmaceuticals, Alderley Edge, Cheshire, UK.

parallel To whom correspondence should be addressed. Tel.: 32-14-602618 or 32-14-605734; Fax: 32-14-606111; E-mail: wluyten{at}janbe.jnj.com.

1 The abbreviations used are: EST, expressed sequence tag; RACE, rapid amplification of cDNA ends; PCR, polymerase chain reaction; ORF, open reading frame; FISH, fluorescence in situ hybridization; DAPI, 4',6-diamidino-2-phenylindole; kb, kilobase pair(s).

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Hartwell, L. H., and Weinert, T. A. (1989) Science 246, 629-634[Medline] [Order article via Infotrieve]
  2. Hartwell, L. H., and Kastan, M. B. (1994) Science 266, 1821-1828[Medline] [Order article via Infotrieve]
  3. Elledge, S. J. (1996) Science 274, 1664-1672[Abstract/Free Full Text]
  4. Hartwell, L. (1992) Cell 71, 543-546[Medline] [Order article via Infotrieve]
  5. Carr, A. M., and Hoekstra, M. F. (1995) Trends Cell Biol. 5, 32-40[CrossRef]
  6. Savitsky, K., et al.. (1995) Science 268, 1749-1753[Medline] [Order article via Infotrieve]
  7. Bentley, N. J., Holtzman, D. A., Flaggs, G., Keegan, K. S., DeMaggio, A., Ford, J. C., Hoekstra, M., and Carr, A. M. (1996) EMBO J. 15, 6641-6651[Abstract]
  8. Cimprich, K. A., Shin, T. B., Keith, C. T., and Schreiber, S. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2850-2855[Abstract/Free Full Text]
  9. Lieberman, H. B., Hopkins, K. M., Nass, M., Demetrick, D., and Davey, S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13890-13895[Abstract/Free Full Text]
  10. al-Khodairy, F., Fotou, E., Sheldrick, K. S., Griffiths, D. J., Lehmann, A. R., and Carr, A. M. (1994) Mol. Cell. Biol. 5, 147-160
  11. Furnari, B., Rhind, N., and Russell, P. (1997) Science 277, 1495-1497[Abstract/Free Full Text]
  12. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997) Science 277, 1497-1501[Abstract/Free Full Text]
  13. Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H. (1997) Science 277, 1501-1505[Abstract/Free Full Text]
  14. al-Khodairy, F., and Carr, A. M. (1992) EMBO. J. 11, 1343-1350[Abstract]
  15. Griffiths, D. J. F., Barbet, N. C., McCready, S., Lehmann, A. R., and Carr, A. M. (1995) EMBO J. 14, 5812-5823[Abstract]
  16. Lee, S. H., and Hurwitz, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5672-5676[Abstract]
  17. Lee, S. H., Kwong, A. D., Pan, Z. Q., and Hurwitz, J. (1991) J. Biol. Chem. 266, 594-602[Abstract/Free Full Text]
  18. Lee, S. H., Pan, Z. Q., Kwong, A. D., Burgers, P. M. J., and Hurwitz, J. (1991) J. Biol. Chem. 266, 22707-22717[Abstract/Free Full Text]
  19. Tsurimoto, T., and Stillman, B. (1991) J. Biol. Chem. 266, 1950-1960[Abstract/Free Full Text]
  20. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410[CrossRef][Medline] [Order article via Infotrieve]
  21. Leupold, U. (1970) Methods Cell Physiol. 4, 169-177
  22. Maundrell, K. (1993) Gene (Amst.) 123, 127-130[CrossRef][Medline] [Order article via Infotrieve]
  23. Ito, H., Fukuda, Y., Murata, K., and Kimura, A. (1983) J. Bacteriol. 153, 163-168[Medline] [Order article via Infotrieve]
  24. Heng, H. H. Q., Squire, J., and Tsui, L.-C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9509-9513[Abstract]
  25. Heng, H. H. Q., and Tsui, L.-C. (1993) Chromosoma (Berl.) 102, 325-332[Medline] [Order article via Infotrieve]
  26. Heng, H. H. Q., and Tsui, L.-C. (1994) Methods Mol. Biol. 33, 35-49[Medline] [Order article via Infotrieve]
  27. Kaiser, C., Michaelis, S., and Mitchell, A. (1994) Methods in Yeast Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  28. Lee, M. G., and Nurse, P. (1987) Nature 327, 31-35[CrossRef][Medline] [Order article via Infotrieve]
  29. Tirkkonen, M., Johannsson, O., Agnarsson, B. A., Olsson, H., Ingvarsson, S., Karhu, R., Tanner, M., Isola, J., Barkardottir, R. B., Borg, A., and Kallioniemi, O.-P. (1997) Cancer Res. 57, 1222-1227[Abstract]
  30. Nagai, H., Pineau, P., Tiollais, P., Buendia, M. A., and Dejean, A. (1997) Oncogene 14, 2927-2933[CrossRef][Medline] [Order article via Infotrieve]
  31. Schwendel, A., Langreck, H., Reichel, M., Schrock, E., Reid, T., Dietel, M., and Petersen, I. (1997) Int. J. Cancer 74, 86-93[CrossRef][Medline] [Order article via Infotrieve]
  32. Petersen, I., Langreck, H., Wolf, G., Schwendel, A., Psille, R., Vogt, P., Reichel, M. B., Ried, T., and Dietel, M. (1997) Br. J. Cancer 75, 79-86[Medline] [Order article via Infotrieve]
  33. Verhaegh, G. W., Jongmans, W., Jaspers, N. G., Natarajan, A. T., Oshimura, M., Lohman, P. H., and Zdzienicka, M. Z. (1995) Am. J. Hum. Genet. 57, 1095-1103[Medline] [Order article via Infotrieve]
  34. Parkinson, E. K., Newbold, R. F., and Keith, W. N. (1997) Eur. J. Cancer 5, 727-734
  35. Li, B., and Fields, S. (1993) FASEB J. 7, 957-963[Abstract/Free Full Text]
  36. Iwabuchi, K., Li, B., Bartel, P., and Fields, S. (1993) Oncogene 8, 1693-1696[Medline] [Order article via Infotrieve]
  37. Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., and Xiong, Y. (1994) Genes & Dev. 8, 2939-2952[Abstract]
  38. Kato, R., and Ogawa, H. (1994) Nucleic Acids Res. 22, 3104-3112[Abstract]
  39. Keegan, K. S., Holtzman, D. A., Plug, A. W., Christenson, E. R., Brainerd, E. E., Flaggs, G., Bentley, N. J., Taylor, E. M., Meyn, M. S., Moss, S. B., Carr, A. M., Ashley, T., and Hoekstra, M. (1996) Genes Dev. 10, 2423-2437[Abstract]
  40. Weinert, T. A., and Hartwell, L. H. (1990) Mol. Cell. Biol. 10, 6554-6564[Medline] [Order article via Infotrieve]
  41. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. (1992) Cell 70, 937-948[Medline] [Order article via Infotrieve]
  42. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. (1992) Cell 70, 923-936[Medline] [Order article via Infotrieve]
  43. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. (1991) Cancer Res. 51, 6304-6311[Abstract]
  44. Kastan, M. B., Zhan, Q., el-Diery, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. (1991) Cell 71, 587-597
  45. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. (1992) Proc. Natl. Acad. Sci U. S. A. 89, 7491-7495[Abstract]
  46. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tlsty, T. D., Lees, E., Harper, J. W., Elledge, S., and Reed, S. I. (1994) Cell 76, 1013-1023[Medline] [Order article via Infotrieve]
  47. Lydall, D., and Weinert, T. (1995) Science 270, 1488-1491[Abstract]
  48. Carr, A. M. (1994) Int. J. Radiat. Biol. 66, (suppl.) 133-139
  49. Parker, A. E., Van de Weyer, I., Laus, M. C., Oostveen, I., Yon, J., Verhasselt, P., and Luyten, W. H. M. L. (1998) J. Biol. Chem. 273, 18332-18339[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.